MedTrace Logo

Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis

NCT03113721 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 571

Last updated 2019-01-09

No results posted yet for this study

Summary

The purpose of this prospective, non-interventional, multi-centre clinical study is to assess the clinical validity of the Heparin Binding Protein (HBP) assay for indicating the presence, or outcome, of severe sepsis (including septic shock), over 72 hours, in patients with suspected infection following emergency department admission.

Conditions

  • Sepsis
  • Septic Shock
  • Sepsis With Acute Organ Dysfunction

Sponsors & Collaborators

  • Drexel University

    collaborator OTHER

  • York Hospitals

    collaborator OTHER

  • Jefferson Medical College of Thomas Jefferson University

    collaborator OTHER

  • Vanderbilt University Medical Center

    collaborator OTHER

  • Baylor College of Medicine

    collaborator OTHER

  • Axis Shield Diagnostics Ltd

    lead INDUSTRY

Principal Investigators

  • Theodore Corbin, MD · Drexel University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2018-12-31
Completion
2019-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03113721 on ClinicalTrials.gov